Recently, Johnston et al. (2014) identified a critical role for TIGIT in regulating exhausted CD8+ T cell responses in cancer and chronic infections and additionally identified the TIGIT/CD226 pathway, which provides significant interest for a combined blockade with the PD-1 pathway in order to strengthen the CD8+ T cell response17. This evidence concerns the gene CD226 and cancer.